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Introduction {#sec1}
============

Irradiation or chemotherapy followed by allogenic stem cell transplantation is a major therapeutic approach for the treatment of leukemia and other malignant and non-malignant diseases ([@bib10], [@bib20], [@bib39], [@bib51], [@bib56], [@bib65]). High transplantation efficiency is beneficial for both patients and donors ([@bib3], [@bib10], [@bib59]). Hematopoietic stem cell (HSC) engraftment, proliferation, and differentiation are critically regulated by niche microenvironments, which involve endothelial cells (ECs) and vessel-associated mesenchymal cells ([@bib9], [@bib11], [@bib14], [@bib15], [@bib23], [@bib30], [@bib32], [@bib49], [@bib57], [@bib58], [@bib61], [@bib63], [@bib72]). Whereas it is proposed that lethal irradiation triggers acute loss of ECs, vessel dilation or swelling and changes in permeability have been also reported ([@bib6], [@bib16], [@bib26], [@bib29], [@bib33], [@bib44], [@bib62], [@bib73]). Thus, our understanding of irradiation and chemotherapy-induced vascular damage and the factors promoting regeneration remain insufficient.

In development but also in the adult skeletal system, ECs are heterogeneous and form different subpopulations ([@bib4], [@bib34], [@bib41], [@bib43], [@bib57], [@bib67]). It is unclear whether all capillary ECs are equally important for hematopoiesis and HSC maintenance. Apelin, encoded by gene *Apln*, is a secreted peptide whose function is reported to be redundant with Elabela/Apela ([@bib27], [@bib31], [@bib37], [@bib40]). Apelin is primarily secreted from a subset of capillary ECs, namely, Apln^+^ ECs, which can be genetically targeted by *Apln-CreER* knockin mice ([@bib8], [@bib45], [@bib66]). In the growing retinal vasculature, *Apln* expression is enriched in tip ECs at the distal end of vessel sprouts ([@bib13]). Apln expression also marks highly proliferative ECs in many developing organs ([@bib43], [@bib45], [@bib55]), whereas Apln^+^ ECs largely disappear in the adult vasculature consistent with its quiescent, non-proliferative status ([@bib45]).

Here, we have combined inducible mouse genetics, flow cytometry, RNA sequencing (RNA-seq), and advanced imaging approaches to show that adult Apln^+^ ECs are critical for the maintenance of steady-state hematopoiesis as well as vascular regeneration and hematopoietic reconstitution after bone marrow (BM) transplantation.

Results {#sec2}
=======

Irradiation-Induced Changes in Bone ECs {#sec2.1}
---------------------------------------

Making use of advanced bone processing and imaging protocols, we found that lethal total body irradiation (9 Gy) of adult mice results in profound alterations of the long bone vasculature at 7 days post-irradiation, including the disruption of columnar capillaries in the metaphysis, dilation of sinusoidal capillaries in the diaphysis, and expansion of the vascular area in bone, visualized by immunostaining of the sialoglycoprotein Endomucin (Emcn) ([Figures 1](#fig1){ref-type="fig"}A--1D and [S1](#mmc1){ref-type="supplementary-material"}A--S1C). Irradiation also causes an increase in vessel permeability, as indicated by enhanced tracer extravasation ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Whereas CD31^+^ Emcn^--^ hematopoietic cells are largely absent after irradiation, endothelial CD31 expression is upregulated, and vessel-associated collagen IV^+^ reticular fibers are disrupted ([Figure 1](#fig1){ref-type="fig"}C). At 1 day after irradiation, BM vascular morphology is already changed with higher expression of Emcn relative to 3 h post-irradiation ([Figure S1](#mmc1){ref-type="supplementary-material"}D). At 4 days post-irradiation, alterations in vascular morphology, such as vessel dilation, are more profound, indicating dynamic changes over several days ([Figure S1](#mmc1){ref-type="supplementary-material"}D). To reveal the morphological changes of ECs at single-cell level, we treated *Cdh5(PAC)-CreERT2 Rosa26-mTmG* double-transgenic mice ([Table S1](#mmc1){ref-type="supplementary-material"}) with low doses of tamoxifen. The analysis of rare recombined and therefore isolated GFP^+^ cells indicates substantial changes in EC size and shape complexity at single-cell resolution ([Figures 1](#fig1){ref-type="fig"}E and 1F). Next, we checked the density of ECs after irradiation, which was aided by *Cdh5(PAC)-mtdTomato-nGFP* (*Cdh5-mTnG*) reporter mice in which membrane-anchored tdTomato fluorescent protein labels the surface and histone H2B-coupled GFP (nGFP) the nuclei of ECs ([@bib35]) ([Table S1](#mmc1){ref-type="supplementary-material"}). Confirming the specificity of this reporter, H2B-GFP signal co-localizes with nuclear ERG, a transcription factor and EC marker, in postnatal day (P) 6 heart endothelium but not in the EC-derived mesenchymal cell in heart valves ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Further proving that *Cdh5-mTnG* reporter marks genuine ECs but not EC-derived cell populations, GFP signal in bone decorates Emcn^+^ and VEGFR2^+^ (vascular endothelial growth factor receptor 2^+^) ECs without labeling CD31^+^ Emcn^--^, B220^+^, and lineage committed hematopoietic cells ([Figures S1](#mmc1){ref-type="supplementary-material"}F--S1J). Lethal irradiation of adult *Cdh5-mTnG* mice revealed a significant increase in EC density and percentage both by analysis of bone sections and flow cytometry ([Figures 1](#fig1){ref-type="fig"}G and 1H). Moreover, a higher number and ratio of GFP^+^EdU^+^ signals are detected in *Cdh5-mTnG* bone sections after irradiation ([Figure S1](#mmc1){ref-type="supplementary-material"}K). In contrast, active caspase 3 immunostaining and annexin V binding, which indicate apoptosis, are not increased in bone ECs at 3 or 24 h post-irradiation ([Figures S1](#mmc1){ref-type="supplementary-material"}L and S1M). These results show that irradiation disrupts the normal organization of bone capillaries and leads to increases in EC density and vascular permeability.Figure 1Irradiation-Induced Changes in the Vasculature of BM and Spleen(A) Schematic representation of protocol for lethal irradiation analysis.(B) Tile scan overview images of Emcn-stained vessels in adult femur after irradiation.(C) Emcn, CD31, and collagen IV immunostaining of control and irradiated BM, as indicated. Arrows mark Emcn^+^ CD31^+^ vessels in middle panel and collagen IV^+^ reticular fiber on the right.(D) Quantification of Emcn^+^ area in imaging field (n = 6 per group).(E) Morphology of individual ECs (arrows) in control and irradiated bones of *Cdh5-CreER R26-mTmG* mice. Low dosage of tamoxifen was injected 6 days after irradiation.(F) Quantification of area, perimeter, and shape factor from control (n = 147 from 3 mice) and 9 Gy (n = 140 from 4 mice) single ECs. Shape factor is a numerical indication of how similar a 2D shape is to a perfect circle, which has a shape factor of 1.(G) Nuclear GFP^+^ (nGFP^+^) ECs in control and irradiated *Cdh5-mTnG* diaphysis. Graph shows quantitation of GFP^+^ cells (n = 6 in each group).(H) FACS plot of GFP^+^ cells from control and irradiated *Cdh5-mTnG* mice. Graph show frequency of GFP^+^ cells (n = 20 in each group).(I) Tile scan overview images and selected maximum intensity projections of spleen vessels in *Cdh5-mTnG* mice. Quantification of GFP^+^ nuclei in each image field (Ctrl n = 6; 9 Gy n = 4) is shown.Error bars, mean ± SEM. p values, two-tailed unpaired Student's t test.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To investigate whether irradiation disrupts the vasculature in other organs, we analyzed different vascular networks in *Cdh5-mTnG* mice. Strikingly, no overt changes in vessel morphology and EC density were visible in retina, heart, skin, and small intestinal villi, which have no extramedullary hematopoietic function ([Figure S1](#mmc1){ref-type="supplementary-material"}N--S1Q). In spleen, a major adult extramedullary organ, lethal irradiation disrupts the white pulp and leads to significant higher density of splenic vessels ([Figure 1](#fig1){ref-type="fig"}I). These findings support that ECs are far more resistant to irradiation than hematopoietic cells and suggest that vascular alterations after irradiation are particularly strong in organs with hematopoietic function. Very similar to irradiation, the chemotherapy drug 5-fluoracil (5-FU) ([@bib53]) induces profound changes in the bone vasculature including expansion of the Emcn^+^ area and dilation of sinusoidal vessels, disruption of collagen IV^+^ reticular fibers, CD31 upregulation in ECs, morphological alterations of ECs at the single-cell level, and increased EC density ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2H).

To identify molecular changes in the bone endothelium after irradiation, we used fluorescence-activated cell sorting (FACS) to isolate GFP^+^ ECs from adult (8--12 weeks old) *Cdh5-mTnG* long bone for RNA-seq analysis. These FACS-sorted GFP^+^ cells show significant enrichment of core EC markers, confirming their endothelial identity ([Figure 2](#fig2){ref-type="fig"}A). Principal-component analysis (PCA) divides normal (control) GFP^+^ ECs and irradiated GFP^+^ ECs (7 days post-irradiation) into two separate clusters, both of which are distinct from other BM cell groups ([Figure 2](#fig2){ref-type="fig"}B). According to unsupervised clustering, normal ECs and irradiated ECs are more similar to hematopoietic cells than to bone mesenchymal cell populations ([Figure 2](#fig2){ref-type="fig"}C). Furthermore, we found that the endothelial transcriptome is significantly changed only 1 day after irradiation ([Figures 2](#fig2){ref-type="fig"}D and 2E). EC transcriptomes at 1 day and 7 days post-irradiation are also significantly different from each other, suggesting dynamic changes consistent with the structural alterations in the bone vasculature at different time points after the treatment ([Figures 2](#fig2){ref-type="fig"}D, 2E, and [S1](#mmc1){ref-type="supplementary-material"}B--S1D). At 7 days after irradiation, GFP^+^ bone ECs show profound changes in their transcription profile with more than 2,000 upregulated genes and downregulated genes at p \< 0.05 significance level relative to control GFP^+^ ECs ([Figures 2](#fig2){ref-type="fig"}F, 2G, and [S2](#mmc1){ref-type="supplementary-material"}I). More than 4,000 differentially expressed genes were also detected between 1 and 7 days after irradiation ([Figure 2](#fig2){ref-type="fig"}H). Several molecular signals associated with vascular niche function are significantly changed in ECs exposed to irradiation ([Figure 2](#fig2){ref-type="fig"}I), whereas genes related to DNA damage and senescence are not significantly altered ([Figures S2](#mmc1){ref-type="supplementary-material"}J and S2K). These data indicate that irradiation substantially changes the transcription profile of bone ECs, including genes associated with EC niche function.Figure 2Irradiation Induces Dynamic Changes in the Transcription Profile of BM ECs(A) Heatmap of selected EC-enriched genes in BM cells, Lin^--^ cells, LSK cells, ECs, irradiated ECs (9 Gy, 7 days), Lepr^+^, and NG2^+^ cells.(B) PCA plot of control and irradiated ECs together with other BM cell types. Data for Lepr^+^ and NG2^+^ cells were previously published ([@bib2]).(C) Sample distance analysis of different BM cell types, as indicated.(D and E) PCA plot (D) and sample distance analysis (E) of ctrl ECs and ECs at 1 day or 7 days after irradiation.(F--H) MA plot showing differentially expressed genes (red dots) between Ctrl ECs and ECs at 7 days after irradiation (9 Gy) (F), Ctrl ECs and ECs at 1 day after irradiation (G), and ECs at 1 and 7 days after irradiation (H), as indicated.(I) Heatmap of selected HSC niche-related genes after irradiation.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Loss of Hematopoietic Cells Phenocopies Irradiation-Induced Vascular Defects {#sec2.2}
----------------------------------------------------------------------------

Irradiation and 5-FU treatment target multiple cell types ([@bib48], [@bib71]). As BM hematopoietic cells are largely eliminated after irradiation and chemotherapy, we reasoned that this loss might be a key contributor to the observed vascular defects. To test this hypothesis, we generated *Vav1-Cre Rosa26-DTR* mice (*DTR*^iΔHC^) expressing diphtheria toxin receptor in hematopoietic cells ([Table S1](#mmc1){ref-type="supplementary-material"}). The *Vav1-Cre* line used in these experiments does not induce recombination in ECs in adult femur ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3D). Moreover, diphtheria toxin injection into *Vav1-Cre* Cre-negative mice has no effect on hematopoietic cells and bone vessels ([Figure S3](#mmc1){ref-type="supplementary-material"}E). In contrast, diphtheria toxin injection in *DTR*^iΔHC^ animals results in significant deletion of hematopoietic cells including Lin^--^ Sca1^+^ cKit^+^ (LSK) multipotent progenitors ([Figures 3](#fig3){ref-type="fig"}A, 3F, [S3](#mmc1){ref-type="supplementary-material"}F, and S3G). This hematopoietic cell ablation model, which is independent of irradiation and chemotherapy, leads to expansion of the Emcn^+^ area, dilation of sinusoidal vessels, higher EC density, morphological alterations of BM ECs, disruption of reticular fibers, and increased permeability ([Figures 3](#fig3){ref-type="fig"}B--3F), phenocopying the vascular alterations after irradiation and 5-FU treatment. Furthermore, RNA-seq analysis of sorted *DTR*^iΔHC^ ECs reveals similar changes in niche-related gene transcripts ([Figures S3](#mmc1){ref-type="supplementary-material"}H--S3J). These data indicate that hematopoietic cells maintain physiological properties of the bone vasculature and suggest the existence of reciprocal interactions between hematopoietic cells and ECs.Figure 3Diphtheria Toxin-Mediated Hematopoietic Cell Ablation Mimics Irradiation-Induced Vascular Defects(A) FACS plot of LSK cells 4 days after diphtheria toxin injection in *DTR*^iΔHC^ and control mice.(B) Tile scan overview images of Emcn-stained vessels in DTA-treated control and *DTR*^iΔHC^ long bone.(C) High-magnification images showing Emcn, CD31, and collagen IV immunostaining in *DTR*^iΔHC^ and control femur.(D) Tile scan images showing extravasation of fluorescent Dextran in *DTR*^iΔHC^ and control long bone.(E) *Cdh5-mTnG*--controlled GFP^+^ EC nuclei and Emcn staining in *DTR*^iΔHC^ and control diaphysis.(F) Quantification of LSK cell number (Ctrl = 4, *DTR*^iΔHC^*=* 5), Emcn^+^ area (Ctrl = 7, *DTR*^iΔHC^*=* 7), Dextran^+^ area (Ctrl = 4, *DTR*^iΔHC^*=* 3), and GFP^+^ cells per image (Ctrl = 7, *DTR*^iΔHC^*=* 7, frequency of GFP^+^ cells by FACS (Ctrl = 11, *DTR*^iΔHC^*=* 8).(G) Representative images and quantification of Emcn^+^ area at 16 days after irradiation and transplantation of 4 × 10^5^ Lin^--^ or Lin^+^ cells (n = 4 in each group)(H) Emcn, GFP^+^ EC nuclei, CD31, and collagen IV at 16 days after irradiation and transplantation of 2 × 10^4^ Lin^--^ or LSK cells. Quantification of Emcn area (LSK = 10, Lin^--^ = 9) and GFP^+^ EC nuclei in each image field (LSK = 9, Lin^--^ = 8).(I) Tile scan overview images showing Dextran extravasation at 16 days after irradiation and transplantation of 2 × 10^4^ Lin^--^ or LSK cells. Quantification of Dextran^+^ area (LSK = 5, Lin^--^ = 5).Error bars, mean ± SEM. p values, two-tailed unpaired Student's t test. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Transplantation of the same number of different hematopoietic cell subpopulations after irradiation showed that non-committed, lineage-negative cells (Lin^--^: Ter119^--^ CD5^--^ CD11b^--^ CD45R^--^ Ly-6G/C^--^) induce vessel regeneration more efficiently than lineage committed cells (Lin^+^) ([Figures 3](#fig3){ref-type="fig"}G and [S3](#mmc1){ref-type="supplementary-material"}K). Multipotent progenitor LSK cells are even more efficient in this assay and induce vessel regeneration within 16 days even when a lower number of cells was transplanted ([Figures 3](#fig3){ref-type="fig"}H, 3I, and [S3](#mmc1){ref-type="supplementary-material"}L). Following the transplantation of LSK cells, recovering BM vessels show improved vessel integrity and a reduction of the Emcn^+^ area, indicating reduced vessel dilation ([Figures 3](#fig3){ref-type="fig"}H and 3I). BM regeneration after irradiation and transplantation does not involve the differentiation of donor-derived LSK cells into ECs in the recipient vasculature ([Figures S3](#mmc1){ref-type="supplementary-material"}N and S3O). Mathematical regression analysis indicates that the number of BM nuclear cells (BMNCs) in a broad range (2 × 10^6^ to 8 × 10^6^ cells) is not proportional to the extent of vessel regeneration ([Figures S3](#mmc1){ref-type="supplementary-material"}M, [S7](#mmc1){ref-type="supplementary-material"}L, and S7Q). These data argue that LSK cells, which are enriched in hematopoietic stem and progenitor cells (HSPCs), have specific properties that promote the recovery of the recipient vasculature after irradiation more efficiently than other hematopoietic cell subsets.

Identification of Apln^+^ ECs in Adult BM {#sec2.3}
-----------------------------------------

Whereas different EC subpopulations have been proposed to provide vascular niches for HSPCs in BM, it is currently unknown whether the recovery of the bone vasculature after irradiation or 5-FU treatment is mediated by all or only certain ECs. *Bmx-CreERT2* transgenic mice enable efficient and irreversible genetic labeling of arterial ECs ([@bib18], [@bib70]). To check whether arterial cells contribute to bone vessel regeneration, we generated *Bmx-CreERT2 Rosa26-mTmG* (*Bmx-mTmG*) double-transgenic mice in which tamoxifen injection irreversibly labels arterial ECs and their descendants by GFP expression ([Table S1](#mmc1){ref-type="supplementary-material"}). Irradiation and 5-FU treatment did not induce significant morphological changes of arteries ([Figures S4](#mmc1){ref-type="supplementary-material"}A, S4B, and [S2](#mmc1){ref-type="supplementary-material"}F). *Bmx-CreERT2* mice mediated lineage tracing indicates no apparent contribution of arterial ECs to regenerating sinusoidal vessels after irradiation and BM transplantation ([Figure S4](#mmc1){ref-type="supplementary-material"}C) ([@bib18], [@bib70]).

Apelin (Apln) is a peptide ligand secreted by a subpopulation of angiogenic ECs in different growing and regenerating organs ([@bib66]). To analyze the distribution of Apln^+^ ECs in adult bone, we generated adult *Apln-CreER Rosa26-mTmG* (*Apln-mTmG*) mice and tracked the GFP-labeled ECs shortly (2 days) after tamoxifen injection ([Table S1](#mmc1){ref-type="supplementary-material"}). *Apln-CreER*-labeled cells were predominantly found in the metaphysis, endosteum, and the transition area between the metaphysis and diaphysis ([Figure 4](#fig4){ref-type="fig"}A). GFP^+^ cells express Emcn, CD31, VEGFR2, VEGFR3, and VE-cadherin confirming their endothelial identity ([Figures 4](#fig4){ref-type="fig"}B, 4C, and [S4](#mmc1){ref-type="supplementary-material"}H). Apln^+^ ECs express Sca-1 but are, unlike arterial ECs, not covered by αSMA^+^ vascular smooth muscle cells (vSMCs) ([Figure S4](#mmc1){ref-type="supplementary-material"}I). FACS-isolated *Apln-CreER*-labeled ECs represent about 0.0032% ± 0.0003% of total BM cells and 12.4% ± 1.3% of bone ECs ([Figures 4](#fig4){ref-type="fig"}D and 4E). Strikingly, Apln^+^ EC are closely associated with a subset of CD150^+^ CD48^--^ Lin^--^ HSCs that are located in the metaphysis and the transition zone between the metaphyseal and diaphyseal vasculature ([Figures 4](#fig4){ref-type="fig"}F and 4G). To understand whether Apln^+^ ECs are similar to other BM ECs, we isolated *Apln-CreER*-labeled (GFP^+^) cells from *Apln-mTmG* mice by FACS for RNA-seq analysis. These cells were compared to ECs from the *Cdh5-mTnG* diaphysis ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Confirming their endothelial identity, both sorted cell populations show significantly higher expression of EC markers relative to other BM cells, but they also show substantial differences in gene expression and form separate clusters in principal components analysis ([Figures 4](#fig4){ref-type="fig"}H and [S4](#mmc1){ref-type="supplementary-material"}E). While 2,609 genes are significantly enriched in Apln^+^ ECs, 2,544 genes show significantly higher expression in the diaphyseal endothelium ([Figures 4](#fig4){ref-type="fig"}I and [S4](#mmc1){ref-type="supplementary-material"}F). Based on Gene Ontology (GO) biological process analysis, most of the 15 top enriched pathways in Apln^+^ ECs are related to angiogenesis and, in particular, vascular endothelial growth factor (VEGF) signaling ([Figure 4](#fig4){ref-type="fig"}J). In contrast, pathways enriched in diaphyseal ECs relate to leukocyte adhesion, tethering and rolling, which is consistent with the known function of sinusoidal vessels in the trafficking of hematopoietic cells ([Figure S4](#mmc1){ref-type="supplementary-material"}G). Accordingly, numerous mRNAs associated with HSC niche function of the endothelium, such as *Ptn* (encoding Pleiotrophin), gap-junction proteins, and Notch ligands are substantially higher in Apln^+^ ECs ([Figure 4](#fig4){ref-type="fig"}K) ([@bib24], [@bib28], [@bib64], [@bib67]), suggesting that Apln^+^ ECs may potentially play a role in hematopoiesis. In addition, Apln^+^ ECs have special molecular properties and show expression of certain arterial markers, such as *Dll4* (Delta-like 4), *Efnb2* (ephrin-B2), *Ly6a* (Sca-1), *Gja1* (connexin 43), *Cav1* (caveolin-1), and the transcription factor *Sox17*, even though they are not typical arterial cells based on their localization and the lack of αSMA^+^ cell coverage ([Figures 4](#fig4){ref-type="fig"}K, [S4](#mmc1){ref-type="supplementary-material"}E, and S4I). These data indicate that Apln^+^ ECs in adult bone represent a specialized endothelial subpopulation.Figure 4Identification of Apln^+^ ECs in Adult BM(A) Confocal tile scan images (left) showing distribution of GFP^+^ cells in *Apln-mTmG* mice. High magnifications (right) show enlarged regions of the metaphysis and diaphysis. Arrows mark GFP^+^ cells in endosteum.(B and C) Emcn and CD31 (B) and VEGFR2 and VEGFR3 (C) staining in adult *Apln-mTmG* femur. Arrows mark GFP^+^ ECs.(D) FACS plots of GFP^+^ cells isolated from *Apln-mTmG* mice.(E) Histogram of Emcn expression in GFP^--^ and GFP^+^ cells. Quantification of mean fluorescence intensity (MFI) in GFP^--^ and GFP^+^ cells (n = 3 per group). Error bars, mean ± SEM. p values, two-tailed unpaired Students' t test.(F) CD150^+^ Lin^--^ CD48^--^ HSC (arrow) and GFP^+^ EC in the metaphysis and metaphysis-diaphysis transition area of *Apln-mTmG* mice.(G) Distribution of distance between DAPI^+^ cells (n = 3,872) or CD150^+^ Lin^--^ CD48^--^ HSCs (n = 52) and GFP^+^ ECs cells in the metaphysis and metaphysis-diaphysis transition area of *Apln-mTmG* mice.(H) PCA plot of total BM cells (BMC), Apln^+^ ECs (from whole bone), and diaphyseal ECs (DP ECs).(I) MA plot showing differentially expressed genes between Apln^+^ ECs and DP ECs.(J) Top 15 enriched pathways in GO analysis in Apln^+^ ECs relative to DP ECs.(K) Heatmap of selected genes in Apln^+^ ECs.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Apln^+^ ECs Regulate Steady-State Hematopoiesis {#sec2.4}
-----------------------------------------------

To investigate the function of Apln^+^ ECs, we generated *Apln-CreER Rosa26-DTA* (*DTA*^iΔApln^) mice enabling tamoxifen-induced elimination of Apln^+^ ECs ([Figure S4](#mmc1){ref-type="supplementary-material"}M). This procedure damages metaphyseal vessels in direct proximity of the growth plate, results in slight dilation of sinusoidal vessels in the diaphysis, and increases the permeability of the bone vasculature ([Figures S4](#mmc1){ref-type="supplementary-material"}N and S4O). Notably, vascular defects in the *DTA*^iΔApln^ model are morphologically distinct from the damage seen after myeloablative treatments, namely, irradiation, 5-FU, or the *DTR*^iΔHC^ model ([Figures S4](#mmc1){ref-type="supplementary-material"}N, [1](#fig1){ref-type="fig"}B, 1C, [S2](#mmc1){ref-type="supplementary-material"}B, [3](#fig3){ref-type="fig"}B, and 3C). Based on flow cytometric analysis, the ablation of Apln^+^ ECs leads to profound reductions in the percentage and absolute number of LSK cells and HSCs ([Figures 5](#fig5){ref-type="fig"}A and 5B). The remaining CD150^+^ CD48^--^ Lin^--^ HSCs are found in larger distance from BM vessels in *DTA*^iΔApln^ mice ([Figure 5](#fig5){ref-type="fig"}C). Depletion of long-term HSCs in *DTA*^iΔApln^ bone was confirmed by CD45.1/CD45.2 long-term competitive repopulation experiments ([Figures 5](#fig5){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}A). We also detected a significant decrease of common lymphoid progenitors and common myeloid progenitors ([Figure 5](#fig5){ref-type="fig"}B), indicating that Apln^+^ ECs are required for the maintenance of both multipotent and oligopotent HSPCs. The number of BMNCs is not significantly altered, whereas the percentage of B lymphocytes decreases significantly in *DTA*^iΔApln^ bone ([Figure S5](#mmc1){ref-type="supplementary-material"}B). In contrast, the percentages of CD45^--^ Ter119^--^ CD31^--^ CD51^+^ CD140a^+^ and of CD45^--^ Ter119^--^ CD31^--^ Lepr^+^ CD140b^+^ perivascular cells are not changed significantly ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Peripheral blood (PB) count results show a significant decrease of lymphocyte and increase in the percentage of granulocytes in *DTA*^iΔApln^ mice relative to control ([Figure S5](#mmc1){ref-type="supplementary-material"}D). FACS analysis indicates a significantly higher percentage of myeloid cells in *DTA*^iΔApln^ PB, whereas the percentage of total CD45^+^ leukocytes is not significantly changed ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Moreover, certain proinflammatory cytokines, in particular, interleukin (IL)-1α and IL-6, are elevated in blood plasma of *DTA*^iΔApln^ mice ([Figure S5](#mmc1){ref-type="supplementary-material"}F). The percentage change of myeloid cells and B lymphocyte are also seen in liver but not spleen of *DTA*^iΔApln^ mice ([Figures S5](#mmc1){ref-type="supplementary-material"}G and S5H). These results indicate that Apln^+^ ECs help to maintain a normal, non-inflammatory milieu and play a critical role in steady-state hematopoiesis.Figure 5Apln^+^ ECs Regulate HSC Maintenance and Steady-State Hematopoiesis(A) FACS plot of LSK cells and HSCs in control and *DTA*^iΔApln^ mice. Numbers in boxes represent the percentage of the cell population among all BM cells.(B) Quantification of the number and percentage of LSK cells, HSCs, and oligopotent progenitor cells in control (n = 10) and *DTA*^iΔApln^ (n = 10) mice. CLP, common lymphoid progenitor; CMP, common myeloid progenitor.(C) Quantitative distribution of distance between CD150^+^CD48-Lin^--^ HSCs and vessels in whole BM of control (n = 40 HSC from 4 mice) and *DTA*^iΔApln^ mice (n = 40 HSC from 5 mice).(D) Long-term competitive repopulation assay showing donor-derived (CD45.2, control = 11 and *DTA*^iΔApln^ = 14) myeloid cells, B cells, and T cells.(E) Percentage of BM HSCs in control (n = 10) and *Kitl*^iΔApln^ mice (n = 10).(F) Long-term competitive repopulation assay showing donor-derived (CD45.2, control = 9 and *Kitl*^iΔApln^ = 12) myeloid cells, B cells, and T cells.(G) Percentage of BM HSCs in control (n = 11) and *Vegfr2*^iΔApln^ mice (n = 11).(H) Long-term competitive repopulating assay showing donor-derived (CD45.2, control = 12 and *Vegfr2*^iΔApln^ = 9) myeloid cells, B cells, and T cells.Error bars, mean ± SEM. p values, two-tailed unpaired Student's t test. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Stem cell factor (SCF, encoded by the gene *Kitl* in mice) is an essential regulator of HSC self-renewal and function ([@bib2], [@bib9], [@bib14], [@bib70]). *Apln-CreER*-mediated inactivation of the *Kitl* gene causes a significantly lower percentage of HSCs in the BM of the resulting *Kitl*^iΔApln^ mutants relative to littermate controls ([Figure 5](#fig5){ref-type="fig"}E). This reduction of HSCs in *Kitl*^iΔApln^ mice is confirmed by CD45.1/CD45.2 long-term competitive repopulating assay ([Figure 5](#fig5){ref-type="fig"}F), whereas the PB count in *Kitl*^iΔApln^ mice is normal ([Figure S5](#mmc1){ref-type="supplementary-material"}I). In Apln^+^ ECs, genetic inactivation of VEGF receptor 2 (*Vegfr2*^iΔApln^), which is the major receptor of VEGF-A, also causes a significant reduction in HSC percentage ([Figures 5](#fig5){ref-type="fig"}G, 5H, and [S5](#mmc1){ref-type="supplementary-material"}J). These results indicate that Apln^+^ ECs and signaling processes in these cells are necessary for HSC maintenance.

*Apln-CreER* mice have been generated by a knockin of tamoxifen-inducible CreER into the X-linked *Apln* locus ([@bib66]), which disrupts the function of the gene globally so that *Apln-CreER* hemizygous male mice (T/y) are null mutants lacking the ability to generate apelin peptide. Excluding the possibility that the defects in *Apln-CreER* males are caused by lost *Apln* function, hematopoiesis and hematopoietic reconstitution are comparable for *Apln-CreER* hemizygous (T/y) and littermate wild-type (+/y) male mice in the absence of tamoxifen treatment ([Figures S5](#mmc1){ref-type="supplementary-material"}K and S5L). Together, these results indicate that a small subpopulation of Apln^+^ ECs but not apelin expression is required for steady-state hematopoiesis and HSC maintenance.

Role of Apln^+^ ECs in BM Transplantation and Vascular Regeneration {#sec2.5}
-------------------------------------------------------------------

To investigate potential functional roles of Apln^+^ ECs in hematopoietic reconstitution, we transplanted BM cells into *DTA*^iΔApln^ and littermate control recipients. Transplantation of genetically labeled (GFP^+^) BM cells from *Vav1-Cre Rosa26-mTmG* donors and immunostaining of bone sections and quantitative FACS suggested limited engraftment and expansion of transplanted hematopoietic cells in BM of *DTA*^iΔApln^ recipients at 5 days after lethal irradiation, indicating that Apln^+^ ECs are necessary for efficient transplantation ([Figures 6](#fig6){ref-type="fig"}A--6D). To understand how Apln^+^ ECs contribute to hematopoietic reconstitution, we performed lineage tracing experiments. Adult *Apln-mTmG* were treated with 4-hydroxytamoxifen (4-OHT) at 1 day before lethal irradiation and transplantation, whereas control *Apln-mTmG* mice received the same dosage of 4-OHT without irradiation. In these latter animals, the distribution of *Apln-CreER*-labeled ECs is not substantially changed between 1 and 22 days after 4-OHT administration ([Figures 6](#fig6){ref-type="fig"}E and [4](#fig4){ref-type="fig"}A). In contrast, irradiated *Apln-mTmG* mice show a profound increase of GFP^+^ cells in the diaphyseal vasculature, indicating that the regeneration of bone vessels involves the expansion of Apln^+^ ECs into the diaphyseal (i.e., sinusoidal) vascular network ([Figure 6](#fig6){ref-type="fig"}E). Irradiation without transplantation can trigger similar expansion of Apln^+^ ECs, indicating that this process does not require allogenic BM transplantation ([Figure S6](#mmc1){ref-type="supplementary-material"}D). The descendant cells generated by the expansion of Apln^+^ ECs are reduced but do not regress completely after stable engraftment of the transplanted hematopoietic cells ([Figure S6](#mmc1){ref-type="supplementary-material"}E). The progeny of Apln^+^ ECs includes cells that are covered by αSMA^+^ vSMCs, suggesting adult Apln^+^ ECs have the potential to generate arterial ECs in response to irradiation stress ([Figure S6](#mmc1){ref-type="supplementary-material"}F). Together, these results indicate that Apln^+^ ECs contribute to allogenic transplantation and actively participate in the remodeling of the BM vasculature after irradiation.Figure 6Apln^+^ ECs Are Necessary for BM Transplantation(A) Transplantation of cells from *Vav1-Cre R26-mTmG* mice into Ctrl and *DTA*^iΔApln^ hosts.(B) Tile scan overview images and selected maximum intensity projections of control and *DTA*^iΔApln^ bone 5 days after irradiation and transplantation with 3 × 10^5^*Vav1-Cre R26-mTmG* Lin^--^ cells. Arrows indicate donor-derived GFP^+^ cells.(C) FACS plots of GFP^+^ cells from control and *DTA*^iΔApln^ host BM.(D) Quantification of GFP^+^, GFP^+^CD45^+^, GFP^+^Ter119^+^, and GFP^+^CD11b^+^ cells in control (n = 5) and *DTA*^iΔApln^ (n = 6) host BM.(E) Tile scan overview images and selected maximum intensity projections showing lineage tracing of GFP^+^ cells in *Apln-mTmG* long bone with or without irradiation and transplantation. Arrows mark GFP^+^ Emcn^+^ ECs. Quantification of GFP^+^ area relative to Emcn^+^ area in diaphysis (n = 4 in each group).(F) Quantitative analysis of transplantation efficiency in *DTA*^iΔEsm1^ mice at 5 days after irradiation and transplantation of 10^5^ Lin^--^ cells from *Vav1-mTmG* mice (Ctrl = 8; *DTA*^iΔEsm1^ = 5).(G) Lineage tracing of GFP^+^ cells in *Esm1-CreER R26-mTmG* mice with the same protocol as in (E). Quantification of GFP^+^ area relative to Emcn^+^ area in diaphysis (Ctrl = 4; 9 Gy = 5).(H) PCA plot of Apln^+^ ECs, Esm1^+^ ECs, and total DP ECs under steady state.(I and J) MA plot showing genes with differential expression between Esm1+ ECs and Apln+ ECs (I) and between Esm1+ ECs and total DP ECs (J).(K and L) Heatmap showing expression of selected angiocrine or niche-related genes in Apln^+^ ECs relative to Esm1^+^ ECs (K), and in Esm1^+^ ECs relative to total DP ECs (L).Error bars, mean ± SEM. p values, two-tailed unpaired Student's t test. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

We also investigated another subpopulation of BM ECs, namely, Esm1^+^ ECs, which were genetically labeled in *Esm1-CreER R26-mTmG* mice ([Figure S6](#mmc1){ref-type="supplementary-material"}G) ([@bib55], [@bib60]). Esm1^+^ ECs and Apln^+^ ECs show similar labeling percentages in the diaphysis under steady-state conditions ([Figure S6](#mmc1){ref-type="supplementary-material"}G). In contrast to Apln^+^ ECs, genetic ablation experiments with *Esm1-CreER R26-DTA* mice (*DTA*^iΔEsm1^) ([Figures S6](#mmc1){ref-type="supplementary-material"}H and S6L) fail to influence the percentage of HSCs, BM hematopoietic cell composition, PB composition under steady-state conditions ([Figures S6](#mmc1){ref-type="supplementary-material"}H--S6K), and transplantation efficiency ([Figures 6](#fig6){ref-type="fig"}F and [S6](#mmc1){ref-type="supplementary-material"}L--S6M). Moreover, Esm1^+^ ECs are not preferentially located in the metaphysis and endosteum and fail to expand after irradiation ([Figure 6](#fig6){ref-type="fig"}G). We used FACS to isolate Esm1^+^ ECs ([Figure S6](#mmc1){ref-type="supplementary-material"}N) for RNA-seq analysis. These cells show significant enrichment of core EC markers relative to hematopoietic cells and mesenchymal cells ([Figure S6](#mmc1){ref-type="supplementary-material"}O) but are distinct from Apln^+^ ECs and total diaphyseal ECs ([Figures 6](#fig6){ref-type="fig"}H--6J and [S6](#mmc1){ref-type="supplementary-material"}P). Remarkably, Esm1^+^ ECs show low expression of a broad range of niche factors and angiocrine factors ([Figures 6](#fig6){ref-type="fig"}K and 6L), further arguing that this subpopulation of ECs is not critical for hematopoiesis and transplantation. These results show that not all BM ECs are equally important for HSCs maintenance, hematopoiesis, and transplantation. Moreover, the phenotype in *DTA*^iΔApln^ mutants is most probably induced by specific ablation of Apln^+^ ECs and not by side effects of EC death or unspecific toxicity of diphtheria toxin.

Crosstalk between Apln^+^ ECs and HSPC during BM Regeneration {#sec2.6}
-------------------------------------------------------------

The results above indicate that HSPC/LSK cells and Apln^+^ ECs play critical roles after irradiation and transplantation ([Figures 3](#fig3){ref-type="fig"}G--3I and [6](#fig6){ref-type="fig"}A--6E), which raises the question whether the activity of these cell populations is coupled during hematopoietic reconstitution and bone vessel regeneration. Analysis of RNA-seq results of LSK cells and Lin^--^ HSPCs in combination with previously published data for Lepr^+^ and NG2/Cspg4^+^ perivascular niche cells ([@bib2]) indicates that LSK cells are a major source of VEGF-A (encoded by the gene *Vegfa*) in BM ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Higher expression of VEGF-A protein in LSK cells is confirmed by ELISA ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Irradiation significantly disrupts autocrine expression of *Vegfa* by ECs, which, together with the loss of LSK cells, results in profoundly reduced *Vegfa* expression in total BM cells ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7C). Previous work has shown that donor-cell-derived VEGF-A is necessary for transplantation ([@bib22]). This finding is confirmed by our own transplantation experiments with BM cells from *Vav1-Cre Vegfa* (*Vegfa*^ΔHC^) double-heterozygous mice into lethally irradiated recipients ([Figures S7](#mmc1){ref-type="supplementary-material"}F--S7H) ([@bib19]). However, it was unclear whether hematopoietic cells or ECs are the cellular target of VEGF-A, as both possibilities are favored by different reports ([@bib22], [@bib33]). To address this question, we have combined inactivation the *Kdr* (*Vegfr2*) gene, which encodes the main receptor for VEGF-A, in different cells types. In BM transplantation experiments, donor cells from hematopoietic cell-specific *Vav1-Cre Vegfr2 (floxed/floxed)* (*Vegfr2*^ΔHC^) mutants and control animals do not lead to significant differences in transplantation efficiency or recipient BMNC number ([Figures S7](#mmc1){ref-type="supplementary-material"}I--S7J). However, *Vegfr2*^ΔHC^ BM donor transplantation results in a significant increase of CD11b^+^ myeloid cells relative to control BM ([Figure S7](#mmc1){ref-type="supplementary-material"}J), indicating a role of VEGFR2 in hematopoietic cell differentiation.

Expression of *Vegfr2* is strongly increased in irradiated ECs ([Figure S7](#mmc1){ref-type="supplementary-material"}D), and RNA-seq shows that VEGF signaling pathway components are enriched in Apln^+^ ECs ([Figures 4](#fig4){ref-type="fig"}J and [S7](#mmc1){ref-type="supplementary-material"}E). To test whether Apln^+^ ECs might respond to VEGF-A from transplanted BM cells, we generated tamoxifen-induced adult *Apln-CreER Vegfr2 (floxed/floxed)* (*Vegfr2*^iΔApln^) mutants. Transplantation of Lin^--^ HSPCs into lethally irradiated *Vegfr2*^iΔApln^ animals results in delayed bone vessel normalization, lower abundance of BMNCs, LSK cells, myeloid cells, and B cells, but not T cells, relative to littermate control recipients ([Figures 7](#fig7){ref-type="fig"}A, 7B, and [S7](#mmc1){ref-type="supplementary-material"}K--S7M). In an independent approach, we performed transplantation experiments with pan-endothelial *Cdh5-CreERT2 Vegfr2 (floxed/floxed)* (*Vegfr2*^iΔEC^) recipients ([Figure S7](#mmc1){ref-type="supplementary-material"}N). Relative to littermate control recipients, lethally irradiated *Vegfr2*^iΔEC^ mutants show impaired vascular regeneration, lower percentage of LSK cells, and fewer myeloid cells and B cells at 2.5 weeks after transplantation ([Figure S7](#mmc1){ref-type="supplementary-material"}N).Figure 7Crosstalk of HSPC with Apln^+^ ECs in BM Vascular Regeneration and Hematopoietic Reconstitution(A) Diagram depicting the transplantation of wild-type Lin^--^ cells into Ctrl and *Vegfr2*^iΔApln^ host mice.(B) Bone vessels at 2.5 weeks after transplantation in control or *Vegfr2*^iΔApln^ host mice. Quantification of Emcn^+^ area, percentage of LSK cells, number of BMNCs, B220^+^, CD11b^+^, and CD8^+^ cells in control (n = 10--11) and *Vegfr2*^iΔApln^ (n = 11) host mice.(C) Scheme depicting VEGF-A treatment in combination with transplantation of wild-type Lin^--^ cells.(D) Survival curve of irradiated mice transplanted with 10^4^ Lin^--^ cells and intravenous injection of PBS (vehicle; n = 35) or recombinant VEGF-A (n = 20).(E) Bone vessels at 3 weeks after irradiation and treatment with vehicle (PBS + Lin^--^ cells) or VEGF-A (VEGF-A + Lin^--^ cells). Quantification of Emcn^+^ area, percentage of LSK cells, number of BMNCs, B220^+^, CD11b^+^, and CD8^+^ cells in vehicle (n = 12--14) and VEGF-A (n = 11)-treated mice.(F) Secondary long-term competitive repopulating assay with donor-derived CD45.2 cells from 1^st^ transplant of vehicle or VEGF-A-treated recipients. Graphs show percentage of CD45.2 donor-derived myeloid cells, B cells, and T cells (vehicle = 5, VEGF-A = 7).(G) Confocal tile scan overview and high-magnification images of GFP and Emcn signals in the *Apln-mTmG* diaphysis after infusion of vehicle or VEGF-A. Quantification of GFP^+^ cell relative to Emcn^+^ (vehicle = 3, VEGF-A = 3).(H) *Apln* transcripts in cultured bEnd.3 cells. *Actb* was used as control (vehicle = 11, VEGF-A = 11).(I) Quantification of CFU-GM number, CD45% and CD11b% in methylcellulose assays (700 Lin^--^ HSPC were seeded). Vehicle (n = 8) or VEGF-A (4 μg/ml; n = 8) were added to standard culture medium.Error bars, mean ± SEM. p values, two-tailed unpaired Student's t test. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Conversely, combining the transplantation of a limited number of 10^4^ Lin^--^ BM cells after lethal irradiation with intravenous administration of recombinant VEGF-A improves recipient survival, normalization of the BM vasculature, repopulation efficiency in primary transplantations, and significantly increases HSC frequency relative to vehicle-treated controls ([Figures 7](#fig7){ref-type="fig"}C--7F and [S7](#mmc1){ref-type="supplementary-material"}O--S7R). To understand how VEGF-A improves transplantation efficiency, we administrated VEGF-A to *Apln-mTmG* mice together with tamoxifen. In these experiments, VEGF-A infusion significantly increases the percentage of Apln^+^ ECs in diaphysis ([Figure 7](#fig7){ref-type="fig"}G). VEGF-A also significantly increases the transcription of *Apln* in cultured ECs *in vitro* ([Figure 7](#fig7){ref-type="fig"}H). Thus, VEGF-A can change the molecular properties of ECs in adult BM and endothelial *Apln* expression. Consistent with previous research ([@bib22]), VEGF-A has also direct effects on Lin^--^ HSPCs and promotes the formation of leukocytes in methylcellulose assay *in vitro* ([Figures 7](#fig7){ref-type="fig"}I and [S7](#mmc1){ref-type="supplementary-material"}S).

Discussion {#sec3}
==========

In this study, we provide new insight into the nature of irradiation-induced damage to the bone vasculature and the dynamic changes in BM vessels during regeneration and repopulation. Irradiation leads to vessel dilation, increased EC density, and vascular permeability, which are accompanied by changes in EC morphology and gene expression in bone. These vascular defects are phenocopied by a genetic model of hematopoietic cell ablation and are efficiently rescued by transplantation of multipotent LSK cells, which are a major source of VEGF-A. Furthermore, our work identifies a subpopulation of bone ECs, namely, Apln^+^ ECs, as important regulators of HSC function and BM regeneration after transplantation. While previous work has already established that ECs and associated mesenchymal cells provide niches controlling HSC self-renewal and differentiation ([@bib2], [@bib9], [@bib14], [@bib50], [@bib63], [@bib67], [@bib70]), we now assign critical functional properties to a small subset of Apln^+^ ECs.

Our previous work has shown that neonatal Apln^+^ ECs are enriched in CD31^hi^ Emcn^hi^ (type H and E) ECs, mediate postnatal osteogenesis, and generate other EC subtypes during development ([@bib43]). The current study extends the function of Apln^+^ ECs from osteogenesis to adult hematopoiesis and BM transplantation. Adult Apln^+^ ECs express niche factors, such as connexin gap-junction proteins, Notch ligands, and pleiotrophin (PTN), that have been previously associated with HSPC function and BM reconstitution ([Figure 4](#fig4){ref-type="fig"}K). Expression of PTN, a secreted and matrix-binding growth factor, is increased in BM ECs after myelosuppressive irradiation and EC-specific inactivation of the murine *Ptn* gene impairs HSC regeneration ([@bib28], [@bib30]). These results argue that adult Apln^+^ ECs are an important source of niche factors.

Recent single-cell RNA-seq profiling classifies BM ECs into two groups of cells defined as Stab2^high^ ECs and Ly6a^high^ ECs, the latter includes 11% of total ECs ([@bib67]). Our own data show that Apln^+^ ECs represent approximately 12% of total ECs, and Apln^+^ ECs share a strikingly similar transcription profile with Ly6a^high^ ECs ([Figure S4](#mmc1){ref-type="supplementary-material"}J), suggesting that these two subsets may be identical or overlapping entities. While other endothelial subpopulations, namely, Bmx^+^ arterial ECs and Esm1^+^ capillary ECs, show no appreciable expansion after irradiation, ECs derived from the Apln^+^ population increase substantially in number and expand into the endothelium of the regenerating BM cavity. Hematopoietic reconstitution and vascular regeneration after irradiation are promoted by VEGF-A provided by transplanted BM cells and, in particular, by HSPCs and LSK cells, consistent with previous reports addressing the crucial role of the VEGF pathway in BM regeneration ([@bib22], [@bib33]). Thus, regeneration of the vasculature during hematopoietic reconstitution involves reciprocal interactions between the transplanted BM cells and expanding, niche factor-providing Apln^+^ ECs.

Apln^+^ ECs may play an anti-inflammatory role required to maintain a balanced BM microenvironment. Apln^+^ ECs show enriched expression of anti-inflammatory factors such as *Mmp*, *Tgfb2*, *Nos3*, and *Ptgis* ([@bib1], [@bib5], [@bib36], [@bib46], [@bib17], [@bib38]). Accordingly, ablation of Apln^+^ ECs leads to an increase of PB myeloid cells, which is a hallmark of numerous conditions with compromised BM function including aging, inflammation, or compromised stromal support ([@bib42], [@bib47], [@bib54], [@bib67]).

Based on the findings presented above, we propose that Apln^+^ ECs in the adult skeletal system represent a population of specialized ECs, which are characterized by progenitor properties, are a source of niche factors, control multipotent, and oligopotent hematopoietic progenitors, and promote BM regeneration after myeloablative treatment. Our results provide insights into the cellular and molecular mechanisms controlling BM transplantation and highlight Apln^+^ ECs as a potential therapeutic target in this process.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------
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Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ralf H. Adams (<ralf.adams@mpi-muenster.mpg.de>). This study did not generate new unique reagents.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

8-15 week-old mice were used as young adults and C57BL/6 males were used as wild-type mice for all analysis unless stated otherwise. Genetically modified mouse models used in this study are summarized in [Table S1](#mmc1){ref-type="supplementary-material"}. Littermates with appropriate genotypes were used as controls of genetically modified mutants whenever possible (see further details below).

*Cdh5(PAC)-mtdTomato-nGFP* (*Cdh5-mTnG*) reporter mice were previously described and used for labeling of EC nuclei and FACS-sorting ([@bib35]).

*Vav1-Cre* ([@bib12]) transgenic mice were interbred with *Rosa26-DTR (*[@bib7]*)* animals to generate *Vav1-Cre*^*+/T*^ *Rosa26-DTR*^*+/lox*^ (*DTR*^iΔHC^) mice. *Vav1-Cre*^*+/+*^ *Rosa26-DTR*^*+/lox*^ littermates were used as controls. 25 μg/kg diphtheria toxin (Sigma, D0564) was administrated to *DTR* ^iΔHC^ and control mice for 2 consecutive days and animals were analyzed 4 days after first injection. *DTR* ^iΔHC^ mutants were interbred with *Cdh5-mTnG* animals to generate *Vav1-Cre*^*+/T*^ *Rosa26-DTR*^*+/lox*^ *Cdh5-mTnG*^*+/T*^ triple transgenic mice for the visualization of EC nuclei and flow cytometry analysis. *Vav1-Cre* transgenic mice were interbred with conditional (floxed) *Vegfa* mutants ([@bib21]) mice to generate *Vav1-Cre*^*+/T*^ *Vegfa*^*+/lox*^ (*Vegfa*^ΔHC^) animals and *Vav1-Cre*^*+/+*^ *Vegfa*^*+/lox*^ controls. *Vav1-Cre* transgenic mice were also interbred with conditional (floxed) *Kdr (Vegfr2)* ([@bib25]) mutants to generate *Vav1-Cre*^*+/T*^ *Kdr*^*lox/lox*^ (*Vegfr2*^ΔHC^) mice and *Vav1-Cre*^*+/+*^ *Kdr*^*lox/lox*^ controls.

In the *Rosa26-mTmG* reporter ([@bib52]) background, Cre activity leads to an irreversible switch from constitutive membrane-anchored tdTomato protein expression to membrane-anchored GFP. *Cdh5(PAC)-CreERT2* ([@bib68]) transgenic mice were interbred with *Rosa26-mTmG* reporter animals to generate *Cdh5-CreERT2 Rosa26-mTmG* mice enabling genetic labeling of all ECs. For the morphological analysis of ECs at single cell level, 10 μg tamoxifen (Sigma, T5648) were injected to *Cdh5-CreERT2 Rosa26-mTmG mice* 6 days after irradiation or 5-FU treatment. *Bmx-CreERT2* ([@bib18]) transgenic mice were interbred with the *Rosa26-mTmG* strain to generate *Bmx-CreERT2 Rosa26-mTmG* for genetic labeling of arterial ECs. 500 μg tamoxifen were administered on 2 consecutive days to *Bmx-CreERT2 Rosa26-mTmG* mice for analysis in irradiation experiments with or without transplantation.

*Apln-CreERT2* (T/y) hemizygous males were used for all experiments with this strain to avoid mosaic Cre recombinase expression due to X-inactivation in (T/x) heterozygous females ([@bib66]). *Apln-CreERT2* transgenic animals were bred into the *Rosa26-mTmG* background to generate *Apln-CreERT2 Rosa26-mTmG* (*Apln-mTmG*) mice for genetic labeling, lineage tracing and flow cytometry analysis of Apln+ ECs in bone. 1mg tamoxifen was injected intraperitoneally to *Apln-mTmG* mice on three consecutive days for the labeling and flow cytometric analysis of Apln+ ECs. 1mg 4-hydroxytamoxifen (4-OHT; Sigma, H7904) was injected intraperitoneally at 1 day before irradiation for lineage tracing of Apln+ ECs and their descendants after transplantation. *Apln-CreERT2* transgenic mice were interbred with *Rosa26-DTA* ([@bib69]) animals to generate *Apln-CreERT2*^*T/y*^ *Rosa26-DTA*^*lox/lox*^ (*DTA*^iΔApln^) males and *Apln-CreERT2*^*+/y*^ *Rosa26-DTA*^*lox/lox*^ controls. Two injections of 1mg tamoxifen were used to induce CreERT2 activity and the ablation of Apln+ ECs ([Figure S4](#mmc1){ref-type="supplementary-material"}M). *Apln-CreERT2* transgenic mice were interbred with *Kdr* conditional (floxed) animals to generate *Apln-CreERT2*^*T/y*^ *Kdr*^*lox/lox*^ (*Vegfr2*^iΔApln^) mutants and *Apln-CreERT2*^*+/y*^ *Kdr*^*lox/lox*^ controls. 2 mg tamoxifen were injected on 5 consecutive days to *Vegfr2*^iΔApln^ and control mice for transplantation experiments. *Apln-CreERT2* transgenic mice were interbred with *Kitl*^*tm2.1Sjm*^ (encoding SCF) conditional (floxed) animals to generate *Apln-CreERT2*^*T/y*^ *Kitl*^*lox/lox*^ (*Kitl*^iΔApln^) mutants and *Apln-CreERT2*^*+/y*^ *Kitl*^*lox/lox*^ controls. 2mg tamoxifen were injected on 5 consecutive days to *Kitl*^iΔApln^ and control mice for analysis.

*Cdh5(PAC)-CreERT2* transgenic mice were interbred with *Kdr* conditional (floxed) animals to generate *Cdh5(PAC)-CreERT2*^*+/T*^ *Kdr*^*lox/lox*^ (*Vegfr2*^iΔEC^) mutants and *Cdh5(PAC)-CreERT2*^*+/+*^ *Kdr*^*lox/lox*^ controls. 1mg tamoxifen was injected on 5 consecutive days to *Vegfr2* ^iΔEC^ and control mice for transplantation experiments. *Esm1-CreERT2* transgenic mice were interbred with *Rosa26-mTmG* and *Rosa26-DTA* animals to generate *Esm1-CreERT2*^*+/T*^ *Rosa26-mTmG* and *Esm1-CreERT2*^*+/T*^ *Rosa26-DTA* (*DTA*^iΔEsm1^) mice. *Esm1-Cre* mice were treated with exactly the same tamoxifen injection protocol as *Apln-Cre* animals ([Figures S6](#mmc1){ref-type="supplementary-material"}H and S6L).

All animals were routinely genotyped using respective PCR protocols. Protocols and primer sequences can be provided upon request. All the animals were housed in the animal facility at the Max Planck Institute for Molecular Biomedicine or the Institute for Nutritional Sciences and Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences. All experiments were performed according to the institutional guidelines and laws, following the protocols approved by local and national animal ethics committees.

Method Details {#sec4.4}
--------------

### Cryosectioning, immunohistochemistry and permeability assays {#sec4.4.1}

Adult bones were dissected and immediately placed in ice-cold 4% paraformaldehyde (PFA-PBS) solution and fixed under gentle agitation overnight. Bone samples were placed in 0.5M EDTA (Ph 8.0) for at least 2 days, dehydrated in 20% sucrose-1% polyvinylpyrrolidone PBS solution for at least 2 days, and embedded in PBS containing 15% sucrose, 8% gelatin and 1% polyvinylpyrrolidone for storage at −80°C and cryosectioning on a Leica CM3050 cryostat using low profile blades. For immunostaining, bone sections were rehydrated in PBS, permeabilized for 15 min in 0.5% Triton X-100 PBS solution and blocked for 30 min in PBS containing 1% BSA, 2% donkey serum, 0.3% Trion X100 PBS (blocking buffer) at room temperature. Sections were probed with primary antibodies diluted in blocking buffer at 4°C overnight. After incubation, sections were washed three times with PBS and incubated with appropriate Alexa Fluor-conjugated secondary antibodies (1:100 to 1:400, Invitrogen) diluted in blocking buffer at room temperature for 2 hours. Nuclei were stained with DAPI during secondary antibody incubation. After that, sections were washed three times with PBS, mounted with Fluoromount-G (0100-01, Southern Biotech) and kept in 4°C for imaging.

For the analysis of vascular permeability in bone, 1mg Dextran Texas Red (ThermoFisher Scientific, D1830, 70000MW) was injected into the tail vein. Mice were sacrificed 15 minutes after injection. Femurs were dissected and directly placed in ice-cold 4% PFA for overnight fixation. Further processing of femur samples was exactly the same as for immunostainings. Texas Red signal was excited with a 594nm laser during confocal microscope without signal enhancement.

### Flow cytometry {#sec4.4.2}

Bones were dissected and crushed by pestle for more than 3 times before cells were collected in 2% FCS-PBS solution. The tissue was immersed in 6ml dissociation solution (2% FCS-PBS solution with approximate 145U/ml type 4 GIBCO collagenase) and incubated at 37°C for 30 minutes. Samples were filtered using 70 μm Nylon cell strainer to get single cell suspensions. Reporter mice expressing fluorescent proteins were directly used for flow cytometry. Primary antibodies were diluted in 2% FCS-PBS solution and incubated with cells on ice for 40 minutes. Cells were washed 3 times by 2% FCS-PBS solution and incubated with secondary antibodies for 40 minutes. Cells were washed 3 further times again and used for flow cytometry. Cells were resuspended in PBS/2%FCS supplemented with 1 μg/ml DAPI to allow exclusion of nonviable cells when required. Cell sorting was performed on a FACSAriaIIu cell sorter (BD Biosciences, San Jose, CA) using an 85 μm nozzle. Cell analysis was performed using BD FACS Verse.

### Irradiation, transplantation, lineage separation and VEGF-A treatment {#sec4.4.3}

Mice were exposed to a lethal dose of Gamma irradiation (137Cs, GammaCell 40, Best Theratronics) of 9 Gy and typically analyzed 7 days after irradiation (shown as "9 Gy" in the results), unless another experimental regime is mentioned in the legend. Bone marrow cells (or Lin-/LSK cells) were transplanted 4 to 6 hours after irradiation. For competitive long-term repopulating assays, CD45.1 host mice were lethally irradiated (12 Gy) and transplanted with 5 × 10^5^ donor-derived (CD45.2 background) BM cells together with 5 × 10^5^ host-derived (CD45.1 background) bone marrow cells. Host mice were sacrificed about 16 weeks after transplantation to determine chimerism in bone marrow and peripheral blood using FACS analysis.

For separation of lineage-positive cells, bone marrow cells were collected and filtered as described for flow cytometry analysis. Biotinylated-lineage cocktail antibodies (Miltenyi Biotec, 130-092-613) were mixed with cells at 4°C for 20 minutes. Antibody-conjugated BM cells were washed 2 times and then incubated with anti-biotin antibody-conjugated magnetic microbeads (Miltenyi Biotec, 130-105-637) at 4°C for 30 minutes. The cells were washed 2 times and separated with LS column (MiltenyiBiotec, 130-042-401). Lineage negative or positive cells were counted and transplanted as outlined in the relevant results.

In VEGF-A treatment experiments, 10^4^ lineage-negative cells were transplanted together with 2 μg VEGF-A (Reliatech, 300-076) 4 to 6 hours after lethal irradiation. In the following days, 2 μg VEGF-A or vehicle (PBS) were intravenously injected into recipients as indicated in [Figure 7](#fig7){ref-type="fig"}C. 3 weeks after irradiation, vehicle and VEGF-A treated mice were sacrificed for analysis or for secondary transplantation (long-term repopulating assays). Before intravenous injection, VEGF-A activity was validated in culture ECs.

### Blood count, blood plasma cytokine analysis and bone marrow cell number counting {#sec4.4.4}

Peripheral blood was extracted from the submandicular vein, collected in EDTA-K tube and analyzed with a Scil Vet ABC plus according to the manufacturer's instructions. To analyze peripheral blood cells using FACS, whole blood was centrifuged at 1000 g for 10 minutes and blood plasma was separated. Blood cells layers were resuspended for FACS analysis. The remaining blood plasma was used to calculate cytokine levels by using the Biolegend Legendplex mouse inflammation panel (13-plex; Biolegend, 740446). The experimental process and quantification analysis were performed following the manufacturer's protocol. Data analysis was performed using software provided by Biolegend. Manual gating was used to define beads A and B, while an automatic gating strategy was used to gate individual cytokine in APC-PE plot. Cytokine levels lower than detection level were excluded from analysis.

For counting of BM nucleated cells, BM cells were processed to generate single cell suspensions, as described for flow cytometry analysis. Red blood cells were removed using RBC lysis buffer (ebioscience, 00-4300-54). Total cell numbers were determined using cell counting plates or a Luna 2 automated cell counter (Logos Biosystems). The number of different cell types in BM was calculated based on BMNC counting and flow cytometry analysis with appropriate markers.

### ELISA {#sec4.4.5}

To collect bone marrow supernatant for ELISA analysis, 1 femur was dissected, flushed into 1ml PBS solution and immediately kept on ice. Solutions were centrifuged at 300 g for 5 minutes. Supernatant was stored at −80°C. To collect BM cellular protein for ELISA analysis, Lin- and Lin+ cells were separated. After counting the number of cells, Lin- or Lin+ cells were centrifuged and immersed in NP40 solution with proteinase inhibitor cocktail. The cell-NP40 solution was rotated at 4°C for 30 minutes and then centrifuged at 15000 g for 30 minutes. The remaining supernatant was collected and stored at −80°C. ELISA for VEGF-A was performed with a kit following the manufacturer's instructions (Cloud-Clone Corp, SEA143Mu).

### *In vitro* methycellulose and bEnd.3 assays {#sec4.4.6}

Approximate 700 Lin- cells from wild-type mice were magnetically separated and cultured in MethoCult™ medium (GF M3434, Stem cell technologies) in a 35mm dish. 4μg/ml VEGF-A or vehicle (PBS) were added to the MethoCult™ medium for *in vitro* culture. Lin- HSPCs from the same batch were equally distributed, then exposed to vehicle (PBS) or VEGF-A for half an hour before seeding. Cells and medium were incubated in 37°C 5%CO~2~ cell incubator. 7 days after incubation, CFU number was counted. After counting, cells were washed 4 times with 2% FCS-PBS solution and filtered with 70 μm Nylon cell strainer to get single cell solution for FACS analysis. The FACS staining protocol was the same as for BM cells (see above).

bEnd.3 endothelial cells were cultured in base medium (including DMEM, Glutamine and P/S) plus 5% FCS in 37°C incubator with 5% CO~2~. Cells were passaged into 6 well-plates and, at 70%--80% confluency, the culture medium was changed to base medium plus 1μg/ml VEGF-A or base medium plus PBS vehicle without any serum. The cells were collected into RLT lysis buffer for RNA extraction at 24 hours after a final culture medium change.

### EdU incorporation {#sec4.4.7}

EdU (A10044, Thermofisher scientific) was dissolved in PBS. 40mg/kg EdU-PBS was injected to *Cdh5-mTnG* mice at 7 consecutive days after irradiation. Bone samples were processed as described above. Click-iT EdU Alexa-647 imaging Kit (C10340, Invitrogen) was used to visualize EdU signals. Single optical slices instead of z stacked images were used for data analysis. Co-localization of GFP and EdU signal were analyzed and recorded in Volocity (PerkinElmer).

### RNA extraction and quantitative PCR {#sec4.4.8}

RNA was extracted using RNeasy plus Micro Kit (74034, QIAGEN) and cDNA was generated with iScript™ cDNA Synthesis Kit (\#170-8891, BioRad). Quantitative PCR with reverse transcription was performed with a Bio-rad CFX96 real-time PCR system using FAM-conjugated Taqman probes for *Vegfa* (Mm00437306_m1) and *Apln* (Mm00443562_m1). Gene expression levels were normalized to the endogenous VIC-conjugated *Actb* probe (4352341E) as control.

### RNA sequencing and data analysis {#sec4.4.9}

Total RNAs were extracted using RNeasy Plus Micro kit (QIAGEN) according to the manufacturer's instructions. Quality and quantity of RNA samples were analyzed with a Bioanalyzer and RNA 6000 pico kit (Agilent). Double strand cDNA was synthesized using SMART-Seq v4 Ultra Low Input RNA kit for Sequencing (Takara) and sequencing libraries were constructed with Nextera XT DNA Library Preparation Kit (Illumina) according to the manufacturer's instructions. TruSeq Stranded Total RNA kit (Illumina) was used for the library preparation of total BMC and Lin- samples. The resulting sequencing library was sequenced with 2 × 75 bp paired-end reads on MiSeq or NextSeq 500 sequencer (Illumina). Sequenced reads were aligned to the mouse (mm10) reference genome with TopHat (version 2.1.1), and the aligned reads were used for the transcript quantification by using HTSeq-count (version 0.6.1). DESeq2 was used to identify differentially expressed genes across the samples.

Raw data for Lepr+ and NG2+ cells were derived from previous work ([@bib2]) (GEO accession number: [GSE89811](ncbi-geo:GSE89811){#intref0305}).

### Confocal imaging and image processing {#sec4.4.10}

Stained bone sections were imaged with laser scanning confocal microscopes (Leica SP5 or SP8, Zeiss LSM780) after immunohistochemistry. Quantitative analysis of mutant phenotypes was done with the same microscope and identical imaging acquisition setting for mutant and control samples. Overview images of bone were automatically generated using the tile-scan function of SP5 and LSM780 associated software and the resulting pictures combine multiple individual maximum intensity images. Maximum projections were generated by Volocity or Fiji. Volocity (PerkinElmer), Fiji (open source; <http://fiji.sc/>), Photoshop and Illustrator (Adobe) softwares were used for image processing in compliance with *Cell Stem Cell*'s guide for digital images. In general, original images were loaded into Volocity and brightness-contrast modifications were applied to the whole image. Images exported from Volocity were rotated and cropped in Fiji. Quantification of cell number, length, and area was performed in Volocity and Fiji. Shape factor is a numerical indication of how similar a 2D shape is to a perfect circle. A shape factor of 1 indicates a perfect sphere.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

No statistical methods were used to predetermine sample size. Mice that died before the completion of experimental protocols were excluded from analysis, which was a pre-established criterion before the experiment. No randomization and blinding were used. Samples were tested using two-tailed Student's t test. *P value* less than 0.05 was considered to be statistically significant. Statistical data were drawn from normally distributed group. Before the Student's *t*-Test, samples from different groups were tested using *F*-test to identify the variances between groups. *F* value less than 0.05 indicated samples have significantly different variances. All results are represented as mean ± s.e.m. Number of animals or cells represents biological replicates.

Data and Code Availability {#sec4.6}
--------------------------

RNA-seq raw data supporting this work have been deposited in GEO, under accession number [GSE115422](ncbi-geo:GSE115422){#intref0315}. All original data are available upon reasonable request to Lead Contact.
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